Walgreens Q2 2016 Earnings Review: Acquisition Synergies To Boost Margins Going Forward
Walgreens (NASDAQ:WBA), one of the largest pharmacies in the US released its Q2 2016 earnings on April 5th. (Fiscal years end with August.) The company reported a strong quarter driven by the acquisition of Alliance Boots and growth in Medicare Part D prescriptions . Following is a brief look at the numbers and trends that drove WBA’s performance in the second quarter.
- Will Johnson & Johnson Stock Rebound To Its Pre-Inflation Shock Highs of $185?
- Should You Pick Eli Lilly Stock After A 4x Rise In Three Years?
- Down 9% This Year, What’s Next For Lululemon’s Stock Past Q4 Results?
- Down 14% In The Last Trading Session, Where Is Adobe Stock Headed?
- Will Higher Federal Government Spending, Gen AI Drive Digital Security Stocks Like CrowdStrike Higher?
- Up 30% In A Year Is FedEx Stock A Better Pick Over UPS?
Factors That Will Drive Growth Going Forward
- Rite Aid’s acquisition (expected completion in second half of 2016) will add to the Retail Pharmacy USA business and help grow WBA’s market share
- High Comparable store sales will continue to positively impact revenues driven by the growing Medicare Part D priscriptions
- International Pharmacy and Pharmaceutical Wholesale business will continue to grow
- Higher synergy benefits expected from AmerisouceBergen and refinancing Alliance Boots Indebtedness at a lower cost
Offsetting Factor
- Generic Drugs will continue to adversely impact revenues
Notes:
View Interactive Institutional Research (Powered by Trefis):
Global Large Cap | U.S. Mid & Small Cap | European Large & Mid Cap